Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary spastic paraplegia: from decades of therapy to future innovations.

Therapeutic advances in neurological disorders·2026
Same author

Case Report: Pathogenic <i>PNPLA2</i> variants and nonsense-mediated mRNA decay result in an early-onset neutral lipid storage disease with myopathy.

Frontiers in genetics·2025
Same author

Health-Related Quality-of-Life Outcomes in Patients with Recessive and Dominant LGMD: A Comparative Cross-Sectional Study.

Muscles (Basel, Switzerland)·2025
Same author

Clinical Advances in Neuromuscular Diseases: Neurometabolic Disorders.

Muscles (Basel, Switzerland)·2025
Same author

Limb-Girdle Muscular Dystrophy D2 TNPO3-Related: A Quality of Life Study.

Muscles (Basel, Switzerland)·2025
Same author

<i>Muscles</i>: An Overview of 2023 and Future Perspective.

Muscles (Basel, Switzerland)·2025

Related Experiment Video

Updated: May 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Enzyme replacement therapy for Pompe disease.

Corrado Angelini1, Claudio Semplicini

  • 1Department of Neurosciences, Neuromuscular Laboratory, Campus Pietro d'Abano, University of Padova, Via Orus 2, 35129, Padova, Italy. corrado.angelini@unipd.it

Current Neurology and Neuroscience Reports
|October 18, 2011
PubMed
Summary
This summary is machine-generated.

Enzyme replacement therapy (ERT) offers new hope for glycogen storage disease type II (GSDII) patients. Studies show ERT effectively modifies the disease course, advancing research into GSDII

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

Related Experiment Videos

Last Updated: May 28, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Glycogenosis type II (GSDII), also known as Pompe disease, is a rare autosomal disorder.
  • It results from a deficiency in the lysosomal enzyme acid maltase, crucial for glycogen breakdown.
  • This deficiency leads to glycogen accumulation in lysosomes, causing cellular damage.

Purpose of the Study:

  • To evaluate the efficacy of enzyme replacement therapy (ERT) in patients with GSDII.
  • To explore the impact of ERT on clinical manifestations and pathophysiologic aspects of GSDII.
  • To provide insights into the role of autophagy and immune status in GSDII response to treatment.

Main Methods:

  • Review of recent studies and large patient cohorts on GSDII.
  • Analysis of clinical data from infantile and adult GSDII patients undergoing ERT.
  • Investigation of pathophysiologic markers including autophagy and immune status.

Main Results:

  • ERT has demonstrated effectiveness in modifying the natural course of GSDII.
  • Studies involving large cohorts confirm the positive impact of ERT.
  • ERT has spurred further research into GSDII's clinical and pathophysiologic features.

Conclusions:

  • Enzyme replacement therapy represents a significant advancement in managing GSDII.
  • ERT offers renewed hope and improved outcomes for affected individuals.
  • Ongoing research is deepening the understanding of GSDII, ERT response, and disease mechanisms.